Cambridge, UK-headquartered RxCelerate is a contract research organization (CRO) providing a range of services, including medicinal chemistry, antibody discovery, preclinical safety and efficacy testing.
“With our home in Europe’s largest bioscience cluster, establishing a base in the epicenter of American biotech seemed to be the logical next step. We already have a number of US clients, but this new move brings us right to their doorstep,” said Jill Reckless, CEO of RxCelerate, in a press release.
The new office is located on the Babraham Research Campus in Cambridge, MA.
As part of the move, the company has hired Laura Hamilton to head US operations. Hamilton joined RxCelerate from the Massachusetts Biotechnology Council (MassBio).
“There is huge demand for drug discovery and development services in the greater Boston area, and I look forward to introducing many more companies to the unique RxCelerate approach. I am certain RxCelerate can be as successful in Cambridge, MA, as they have been in Cambridge, UK,” said Hamilton.
RxCelerate has been working with the Department for International Trade (DIT) over the last two years as it looked to expand abroad and develop its international trade strategy, according to the company.
RxCelerate has not responded to a request for comment.